Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1

RIPK1 and RIPK3, two closely related RIPK family members, have emerged as important regulators of pathologic cell death and inflammation. In the current work, we report that the Bcr-Abl inhibitor and anti-leukemia agent ponatinib is also a first-in-class dual inhibitor of RIPK1 and RIPK3. Ponatinib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Rep
Main Authors: Najjar, Malek, Suebsuwong, Chalada, Ray, Soumya S., Thapa, Roshan J., Maki, Jenny L., Nogusa, Shoko, Shah, Saumil, Saleh, Danish, Gough, Peter J., Bertin, John, Yuan, Junying, Balachandran, Siddharth, Cuny, Gregory D., Degterev, Alexei
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494889/
https://ncbi.nlm.nih.gov/pubmed/25801024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2015.02.052
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados